Show simple item record Kovács, Péter Panczel G, Balatoni T, Liszkay G, Gonda, Xénia Bagdy, György Juhász, Gabriella 2015-07-01T18:53:21Z 2015-07-01T18:53:21Z 2015
dc.identifier.citation pagination=579-584; journalVolume=78; journalIssueNumber=6; journalTitle=JOURNAL OF PSYCHOSOMATIC RESEARCH;
dc.identifier.uri doi:10.1016/j.jpsychores.2015.03.005
dc.description.abstract OBJECTIVE: The most frequent serious psychological side effect of immune therapies is depression. In the present study, we tested whether social support, as a positive environmental effect, is able to moderate depression or anxiety symptoms in melanoma patients during adjuvant low-dose interferon treatment. METHODS: Hundred and twenty-seven melanoma patients with negative psychiatric history were included in our longitudinal study and followed up for one year. Depression and anxiety symptoms were measured six times during treatment: at baseline, at 1st, 3rd, 6th, 9th and 12th month of the therapy. In addition, social support was investigated with the Social Dimension Scale. RESULTS: Depressive symptoms significantly increased during the 12-month follow-up period (p<0.001). However, social support significantly moderated the depressogenic effect of low-dose interferon treatment (p<0.001). Patients with better social support showed attenuated increase of depression. Anxiety showed no significant changes during the low-dose interferon treatment (p=0.230). Social support had no moderating effect on anxiety symptoms (p=0.745) during the follow up. DISCUSSION: Our data provide evidence that social support and interferon alpha treatment significantly interact in the development of depression. In addition, our study emphasises that enhancement of social support can reduce depressogenic side effects and increase compliance during adjuvant interferon treatment, and thus, psychological screening and psychooncological counselling should be incorporated in the treatment protocol.
dc.relation.ispartof urn:issn:0022-3999
dc.title Social support decreases depressogenic effect of low-dose interferon alpha treatment in melanoma patients.
dc.type Journal Article 2015-07-01T18:52:37Z
dc.language.rfc3066 en
dc.identifier.mtmt 2871651
dc.identifier.pubmed 25801845
dc.contributor.department SE/GYTK/Gyógyszerhatástani Intézet
dc.contributor.department SE/GYTK/GYHATAS/MTA-SE Neuropszichofarmakológiai és Neurokémiai Kutatócsoport
dc.contributor.department SE/GYTK/GYHATAS/Genetikai Agyi Képalkotó Migrén Kutató Csoport
dc.contributor.department SE/KSZE/Kútvölgyi Klinikai Tömb Klinikai és Kutatási Mentálhigiénés Osztály
dc.contributor.institution Semmelweis Egyetem

Files in this item



This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account